相似文献
1
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.
Oncoimmunology. 2022 Mar 17;11(1):2052411. doi: 10.1080/2162402X.2022.2052411. eCollection 2022.
2
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Cancer Res. 2020 Feb 15;80(4):890-900. doi: 10.1158/0008-5472.CAN-19-2830. Epub 2019 Dec 19.
3
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Medicina (Kaunas). 2023 Mar 10;59(3):544. doi: 10.3390/medicina59030544.
4
Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
Cancer Immunol Res. 2014 Dec;2(12):1220-9. doi: 10.1158/2326-6066.CIR-14-0101. Epub 2014 Oct 16.
5
A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles.
J Extracell Vesicles. 2024 Aug;13(8):e12486. doi: 10.1002/jev2.12486.
6
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5). doi: 10.1073/pnas.2117754119.
7
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.
8
A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.
Int J Biol Sci. 2024 Jan 27;20(4):1279-1296. doi: 10.7150/ijbs.89700. eCollection 2024.
9
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.
EMBO Mol Med. 2017 Oct;9(10):1415-1433. doi: 10.15252/emmm.201607012.
10
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
Life Sci Alliance. 2022 Oct 13;5(12):e202201551. doi: 10.26508/lsa.202201551.
引用本文的文献
1
Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity.
Oncol Res. 2025 Jun 26;33(7):1695-1708. doi: 10.32604/or.2025.060021. eCollection 2025.
2
A lncRNA-mediated metabolic rewiring of cell senescence.
Cell Rep. 2025 Jun 24;44(6):115747. doi: 10.1016/j.celrep.2025.115747. Epub 2025 May 21.
3
Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy.
Aging (Albany NY). 2024 Feb 14;16(4):3531-3553. doi: 10.18632/aging.205544.
本文引用的文献
1
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.
Trends Cancer. 2022 May;8(5):426-444. doi: 10.1016/j.trecan.2022.01.010. Epub 2022 Feb 16.
2
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5). doi: 10.1073/pnas.2117754119.
3
Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome Editing.
Cancer Res. 2021 Oct 15;81(20):5147-5160. doi: 10.1158/0008-5472.CAN-20-1518. Epub 2021 Jul 23.
4
Senescence Inflames the Pancreatic Tumor Microenvironment.
Cell Rep Med. 2020 May 19;1(2):100020. doi: 10.1016/j.xcrm.2020.100020.
5
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy.
Nat Immunol. 2020 Oct;21(10):1160-1171. doi: 10.1038/s41590-020-0751-0. Epub 2020 Aug 3.
6
Cellular Senescence: Defining a Path Forward.
Cell. 2019 Oct 31;179(4):813-827. doi: 10.1016/j.cell.2019.10.005.
7
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952.
8
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
9
The hallmarks of successful anticancer immunotherapy.
Sci Transl Med. 2018 Sep 19;10(459). doi: 10.1126/scitranslmed.aat7807.
10
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
Zotero 插件